CA1307740C - Preparation pharmaceutique et methode permettant d'inhiber la replication du htlv-iii (sida) - Google Patents

Preparation pharmaceutique et methode permettant d'inhiber la replication du htlv-iii (sida)

Info

Publication number: CA1307740C
Authority: CA; Canada
Prior art keywords: dextran sulphate; htlv; iii; pharmaceutical preparation; virus
Prior art date: 1987-08-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA000543641A

Other languages

English (en)

Inventor

Thomas C. Usher

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-08-05

Filing date

1987-08-05

Publication date

1992-09-22

1987-08-05 Application filed by Individual filed Critical Individual

1987-08-05 Priority to CA000543641A priority Critical patent/CA1307740C/fr

1992-09-22 Application granted granted Critical

1992-09-22 Publication of CA1307740C publication Critical patent/CA1307740C/fr

2009-09-22 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

241000700605 Viruses Species 0.000 title claims abstract description 19
230000010076 replication Effects 0.000 title claims abstract description 9
239000000825 pharmaceutical preparation Substances 0.000 title claims description 10
230000002401 inhibitory effect Effects 0.000 title claims description 9
238000000034 method Methods 0.000 title description 5
229920002307 Dextran Polymers 0.000 claims abstract description 31
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims abstract description 30
229910021653 sulphate ion Inorganic materials 0.000 claims abstract description 30
150000003839 salts Chemical class 0.000 claims abstract description 15
208000030507 AIDS Diseases 0.000 claims abstract description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 4
239000005864 Sulphur Substances 0.000 claims abstract description 4
150000001875 compounds Chemical class 0.000 claims abstract description 4
210000002443 helper t lymphocyte Anatomy 0.000 claims abstract description 3
230000001066 destructive effect Effects 0.000 claims abstract 2
230000000694 effects Effects 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
239000000203 mixture Substances 0.000 claims description 3
229910052708 sodium Inorganic materials 0.000 claims description 3
239000011734 sodium Substances 0.000 claims description 3
159000000000 sodium salts Chemical class 0.000 claims description 3
230000005764 inhibitory process Effects 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims 2
239000003937 drug carrier Substances 0.000 claims 1
238000009472 formulation Methods 0.000 claims 1
238000000338 in vitro Methods 0.000 abstract description 3
238000001727 in vivo Methods 0.000 abstract description 3
210000004027 cell Anatomy 0.000 description 7
230000000840 anti-viral effect Effects 0.000 description 5
241001465754 Metazoa Species 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
239000000969 carrier Substances 0.000 description 3
239000003814 drug Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000007774 longterm Effects 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
239000006071 cream Substances 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000012049 topical pharmaceutical composition Substances 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
235000009529 zinc sulphate Nutrition 0.000 description 2
239000011686 zinc sulphate Substances 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
208000005074 Retroviridae Infections Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
229920001448 anionic polyelectrolyte Polymers 0.000 description 1
230000002402 anti-lipaemic effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000036765 blood level Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
WRSZRYQLLVUDNG-UHFFFAOYSA-N formamide;sulfurochloridic acid Chemical compound NC=O.OS(Cl)(=O)=O WRSZRYQLLVUDNG-UHFFFAOYSA-N 0.000 description 1
230000036541 health Effects 0.000 description 1
230000036737 immune function Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
230000035515 penetration Effects 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
229920000867 polyelectrolyte Polymers 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
208000008864 scrapie Diseases 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000019635 sulfation Effects 0.000 description 1
238000005670 sulfation reaction Methods 0.000 description 1
XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000010998 test method Methods 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA000543641A 1987-08-05 1987-08-05 Preparation pharmaceutique et methode permettant d'inhiber la replication du htlv-iii (sida) Expired - Lifetime CA1307740C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000543641A CA1307740C (fr)	1987-08-05	1987-08-05	Preparation pharmaceutique et methode permettant d'inhiber la replication du htlv-iii (sida)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000543641A CA1307740C (fr)	1987-08-05	1987-08-05	Preparation pharmaceutique et methode permettant d'inhiber la replication du htlv-iii (sida)

Publications (1)

Publication Number	Publication Date
CA1307740C true CA1307740C (fr)	1992-09-22

Family

ID=4136200

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000543641A Expired - Lifetime CA1307740C (fr)	1987-08-05	1987-08-05	Preparation pharmaceutique et methode permettant d'inhiber la replication du htlv-iii (sida)

Country Status (1)

Country	Link
CA (1)	CA1307740C (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006003521A1 (fr) *	2004-02-06	2006-01-12	Monash University	Utilisation a haute dose et sur un intervalle court de polysaccharides sulfates dans le traitement des infections

1987
- 1987-08-05 CA CA000543641A patent/CA1307740C/fr not_active Expired - Lifetime

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006003521A1 (fr) *	2004-02-06	2006-01-12	Monash University	Utilisation a haute dose et sur un intervalle court de polysaccharides sulfates dans le traitement des infections

Similar Documents

Publication	Publication Date	Title
DE69023748T2 (de)	1996-05-02	Verwendung von Stickstoff enthaltenden Makrozyklen zur Behandlung retroviraler Infektionen.
Sarin et al.	1987	Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone
US5565448A (en)	1996-10-15	Medicament
Grewal	1981	Pharmacology of 8-aminoquinolines
MD1688F2 (en)	2001-06-30	Benzothiophene, benzofuran and indolethiazepinons, oxazepinons and diazepinons, pharmaceutical composition, method of inhibiting the leucocytes adherence to the endothelial cells for inflammatory diseases treatment and method of treatment of the mammals affected by the HIV infection
TNSN90021A1 (fr)	1991-03-05	Procede de preparation de tetrahydroimidazo (1,4) benzodiazepin -2- thiones antivirales
TNSN89039A1 (fr)	1991-02-04	Tetrahydroimidazo(1,4)benzodiazepin-2-ones antivirales
JPH072663A (ja)	1995-01-06	ウィルス感染治療剤
US4978687A (en)	1990-12-18	Anti-viral agent
EP0183352A2 (fr)	1986-06-04	Utilisation de suramine pour clinothérapie des infections par quelques-uns des membres de la famille des virus humains leucémiques de cellules-T (HTLV) y compris le virus lymphadénopathique (LAV)
US4892876A (en)	1990-01-09	Method for inhibiting HIV and an pharmaceutical composition therefor
CA2195036A1 (fr)	1997-12-08	Composition bactericide, antibacterienne et bacteriostatique
CA2193396A1 (fr)	1995-12-28	Composition pharmaceutique pour prevenir et/ou traiter des infections virales, ainsi qu'eventuellement des inflammations, et utilisation de cette composition
DE3885798T2 (de)	1994-05-19	Proteinhaltiges Polysaccharid zur Behandlung retroviraler Infektionen.
Eagle et al.	1947	The protective action of BAL in experimental antimony poisoning
WO1994003169A1 (fr)	1994-02-17	Melange d'un intercepteur de radicaux libres et d'un chelateur du fer utilise dans le traitement de la depranocytose
US5886000A (en)	1999-03-23	Anti-HIV agent
CA1306694C (fr)	1992-08-25	Preparation pharmaceutique et methode d'inhibition de la replication du virus htlv-iii (sida)
DK167148B1 (da)	1993-09-06	Komplekser af selen- og tellur-ethylendioxy-derivater, farmaceutiske praeparater deraf og anvendelse af komplekserne til fremstilling af farmaceutiske praeparater
Ishii et al.	1989	In vivo efficacy of levamisole against larval stages of Angiostrongylus cantonensis and A. costaricensis
PT97609A (pt)	1992-02-28	Processo para a preparacao de uma composicao farmaceutica para o tratamento de celulas infectadas com o virus da imunodeficiencia humana e dispositivo ou artigo tratado com essa composicao
KR0131323B1 (ko)	1998-04-17	Bu-3608을 함유한 인체면역결핍 바이러스에 대한 항바이러스 조성물
US5264621A (en)	1993-11-23	Anti-virus agent
CZ128095A3 (en)	1995-10-18	Antimalarial medicament
KR950005869B1 (ko)	1995-06-02	위염 치료제

Legal Events

Date	Code	Title	Description
2009-09-22	MKEX	Expiry